Insider Selling: Glaukos Corporation (GKOS) CEO Sells $3,051,871.68 in Stock
Glaukos Corporation (NYSE:GKOS) CEO Thomas William Burns sold 73,788 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total value of $3,051,871.68. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Thomas William Burns also recently made the following trade(s):
- On Tuesday, September 5th, Thomas William Burns sold 1,212 shares of Glaukos Corporation stock. The shares were sold at an average price of $41.25, for a total value of $49,995.00.
Shares of Glaukos Corporation (GKOS) opened at 42.00 on Monday. Glaukos Corporation has a 12-month low of $28.72 and a 12-month high of $52.49. The firm’s market cap is $1.45 billion. The stock’s 50 day moving average price is $38.49 and its 200-day moving average price is $42.55.
Several hedge funds and other institutional investors have recently modified their holdings of GKOS. Teachers Advisors LLC lifted its position in shares of Glaukos Corporation by 5.7% during the 4th quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 1,506 shares during the last quarter. Nationwide Fund Advisors lifted its position in shares of Glaukos Corporation by 749.3% during the 1st quarter. Nationwide Fund Advisors now owns 89,101 shares of the medical instruments supplier’s stock valued at $4,571,000 after buying an additional 78,610 shares during the last quarter. DUPONT CAPITAL MANAGEMENT Corp purchased a new position in shares of Glaukos Corporation during the 1st quarter valued at $776,000. Wells Fargo & Company MN lifted its position in shares of Glaukos Corporation by 73.2% during the 1st quarter. Wells Fargo & Company MN now owns 1,156,562 shares of the medical instruments supplier’s stock valued at $59,332,000 after buying an additional 488,730 shares during the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new position in shares of Glaukos Corporation during the 1st quarter valued at $487,000.
Several equities research analysts have issued reports on the company. Zacks Investment Research raised Glaukos Corporation from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Friday, August 4th. BidaskClub raised Glaukos Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. BMO Capital Markets reaffirmed a “buy” rating and set a $54.00 price target on shares of Glaukos Corporation in a report on Friday, September 1st. Finally, Roth Capital cut their price target on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Glaukos Corporation has an average rating of “Buy” and a consensus price target of $52.33.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.